Tharimmune (THAR) Competitors $2.17 -0.06 (-2.69%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends THAR vs. PHXM, CERO, KPRX, CDT, AEZS, RDHL, AYTU, VINC, SNTI, and NKGNShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include PHAXIAM Therapeutics (PHXM), CERo Therapeutics (CERO), Kiora Pharmaceuticals (KPRX), Conduit Pharmaceuticals (CDT), Aeterna Zentaris (AEZS), RedHill Biopharma (RDHL), Aytu BioPharma (AYTU), Vincerx Pharma (VINC), Senti Biosciences (SNTI), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. PHAXIAM Therapeutics CERo Therapeutics Kiora Pharmaceuticals Conduit Pharmaceuticals Aeterna Zentaris RedHill Biopharma Aytu BioPharma Vincerx Pharma Senti Biosciences NKGen Biotech Tharimmune (NASDAQ:THAR) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment. Which has higher earnings & valuation, THAR or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Tharimmune. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32MN/AN/APHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Does the media refer more to THAR or PHXM? In the previous week, Tharimmune had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 6 mentions for Tharimmune and 2 mentions for PHAXIAM Therapeutics. Tharimmune's average media sentiment score of 0.78 beat PHAXIAM Therapeutics' score of 0.00 indicating that Tharimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tharimmune 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PHAXIAM Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, THAR or PHXM? Tharimmune has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Does the MarketBeat Community believe in THAR or PHXM? Tharimmune and PHAXIAM Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformTharimmuneN/AN/APHAXIAM TherapeuticsN/AN/A Is THAR or PHXM more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% PHAXIAM Therapeutics N/A N/A N/A Do insiders and institutionals have more ownership in THAR or PHXM? 1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryPHAXIAM Therapeutics beats Tharimmune on 5 of the 9 factors compared between the two stocks. Ad WealthPressThe only candlestick pattern worth a darnIt’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…Follow this link here and enter your email address to sign up… Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.22M$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E RatioN/A4.8266.7313.27Price / SalesN/A374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book1.079.636.455.92Net Income-$9.32M$154.43M$119.73M$225.73M7 Day Performance-8.44%-9.46%-5.13%-1.34%1 Month Performance-7.26%-7.27%-2.71%1.15%1 Year Performance-97.24%28.13%31.08%24.02% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune0.5712 of 5 stars$2.17-2.7%N/A-96.8%$3.22MN/A0.002Short Interest ↑Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049CEROCERo TherapeuticsN/A$0.07-0.8%N/AN/A$10.52MN/A0.008Insider SellingShort Interest ↑News CoverageKPRXKiora Pharmaceuticals3.3463 of 5 stars$3.53-1.1%N/A-36.9%$10.48MN/A0.0010Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoveragePositive NewsGap UpCDTConduit PharmaceuticalsN/A$0.11+13.0%N/A-92.7%$10.42MN/A0.003Upcoming EarningsShort Interest ↓Gap UpAEZSAeterna ZentarisN/A$5.72+5.9%N/A-49.9%$10.26M$2.37M-0.3820Analyst ForecastGap UpRDHLRedHill Biopharma1.3178 of 5 stars$8.05-1.3%N/A-96.5%$10.22M$6.53M0.00210Short Interest ↓AYTUAytu BioPharma1.5828 of 5 stars$1.64-9.7%N/A-30.5%$10.09M$81M-0.57160Short Interest ↓News CoverageGap DownHigh Trading VolumeVINCVincerx Pharma3.2176 of 5 stars$0.33+1.6%N/A-59.0%$9.71MN/A-0.2560Analyst RevisionNews CoverageSNTISenti Biosciences0.8336 of 5 stars$2.12-3.6%N/A-44.8%$9.71M$2.56M-0.174News CoverageNKGNNKGen BiotechN/A$0.27-0.4%N/A-90.8%$9.51M$80,000.00-0.05N/AGap Up Related Companies and Tools Related Companies PHAXIAM Therapeutics Competitors CERo Therapeutics Competitors Kiora Pharmaceuticals Competitors Conduit Pharmaceuticals Competitors Aeterna Zentaris Competitors RedHill Biopharma Competitors Aytu BioPharma Competitors Vincerx Pharma Competitors Senti Biosciences Competitors NKGen Biotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THAR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THAR Stock Alerts